NCCN Non-Small Cell Lung Cancer v.1.

2023 – Follow-up – December 12, 2022

Guideline Page Panel Discussion/References Institution Vote

and Request
YES NO ABSTAIN ABSENT

NSCL-24/NSCL-J
Internal request:
Evaluate the data supporting adagrasib as a
subsequent therapy option for patients with
advanced or metastatic NSCLC with KRAS
G12C mutations, whose disease has
progressed on or after initial systemic therapy.
Based on the data in the noted references, the Panel consensus 33 0 0 0
supported the addition of adagrasib as a subsequent therapy
option for patients with advanced or metastatic NSCLC with KRAS
G12C mutations, whose disease has progressed on or after initial
systemic therapy. This is a category 2A recommendation.

External request:
Submission from Mirati Therapeutics,
requesting the inclusion of adagrasib for the
treatment of patients with KRAS G12C-
mutation positive disease, that progressed on
or after initial systemic therapy.
• Janne P, et al. Adagrasib in non-small-cell lung cancer
harboring a KRAS G12C mutation. N Engl J Med
2022;387:120-131.
• See Submission for references.